The stock of ImmunoGen, Inc (NASDAQ:IMGN) closed at $10.74 losing 2.45% in yesterday’s trading session. The latest reports indicate that ImmunoGen, Inc recorded encouraging efficacy and favorable tolerability data. And if all moves according to plan, it is hoped that the data presentation might be taking place any time soon at the annual meeting of the Society of Gynecologic Oncology that will be held in New Orleans, LA.
The company has its findings at hand at the moment after it carried out tests using 14 heavily pre-treated patients. One notable aspect was that it came to the conclusion that the combination of pembrolizumab and mirvetuximab exhibited favorable tolerability and of course that was in line with the known safety profiles that were associated with each and every agent.
An official working with the company has moved ahead to disclose that they would soon be enrolling an additional 35 patients and that has been in close consideration of the data at hand.
The Vice President and Chief Medical Officer of ImmunoGen Anna Berkenblit opined, “We are encouraged by the early evidence of anti-tumor activity with durable responses and the tolerability profile of mirvetuximab in combination with pembrolizumab, specifically among the subset of patients with medium or high folate receptor alpha expression where we experienced the greatest benefit.”
She delved deeper into the matter to outline that across multiple combinations they had as a company managed to give a clear demonstration that their Phase 3 single agent dose level for mirvetuximab readily combined with a wide range of other therapies.
The consistency attributed with much of these findings strongly underscores the potential of mirvetuximab for ovarian cancer as some sort of working monotherapy. And it worked perfectly well with the combination of more therapies in line with other forms of treatment.
An official working with ImmunoGen, Inc after attending a business conference that was held recently addressed several news reporters. He disclosed that they were channeling more funds in the area of research and they hoped that soon they would be able to come up with even better quality remedies to help the large number of ailing persons globally.